Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Interest Income

Income earned on cash, deposits, and investments held by the company.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.

Context

  • Interest income amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Income vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 interest income of $0 is the 8th highest of the 10 companies compared; the peer median is $6.23M.
  • Interest income amounts to 0.0% of revenue for ETON, versus a peer median of 3.6%.
ETON Competitors Peer median
Interest Income for ETON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$89.99M -11.7%+56.9%9.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$24.17M -30.0%+31.2%3.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$12.24M -12.1%+26.6%1.9%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$7.61M +325.6%+66.2%6.2%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$6.23M -50.7%+63.0%8.9%
PHARPharming Group N.V.LTM Mar 2026$4.38M +27.1%+211.0%1.2%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$892.82K -47.3%+59.2%1.8%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding ETON) $6.23M-12.1%+59.2%3.6%

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.83M21.25M31.64M39.01M79.95M
Cost of Revenue2.62M6.93M10.58M15.6M37.21M
Gross Profit19.21M14.32M21.06M23.41M42.74M
Gross Margin88.0%67.4%66.6%60.0%53.5%
Research & Development6.24M4M3.32M3.26M7.77M
Selling, General & Admin14.47M18.58M18.93M22.75M35.82M
Operating Expenses20.7M22.58M22.25M26.01M42.67M
Depreciation & Amortization462K1.77M901K1.15M4.04M
EBITDA(1.49M)(7.25M)212K(657K)4.27M
EBITDA Margin-6.8%-34.1%0.7%-1.7%5.3%
Operating Income(1.5M)(8.26M)(1.19M)(2.6M)72K
Operating Margin-6.8%-38.9%-3.8%-6.7%0.1%
Interest Income00000
Interest Expense1.04M955K1.06M2.01M4.78M
Other Income / Expenses(460K)(761K)503K(1.21M)(4.63M)
Income Before Tax(1.96M)(9.02M)(689K)(3.81M)(4.56M)
Pre-Tax Margin-9.0%-42.4%-2.2%-9.8%-5.7%
Income Tax Expense00247K15K43K
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (Basic)(0.08)(0.36)(0.04)(0.15)(0.17)
EPS (Diluted)(0.08)(0.36)(0.04)(0.15)(0.17)
Weighted Avg Shares25.21M25.15M25.65M25.9M26.91M
Weighted Avg Shares (Diluted)25.21M25.15M25.65M25.9M26.91M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.